A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Trial Profile

A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs GR MD 02 (Primary)
  • Indications Liver cirrhosis; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms NASH-CX
  • Sponsors Galectin Therapeutics
  • Most Recent Events

    • 05 Dec 2017 Results presented in Galectin Therapeutics media release.
    • 04 Dec 2017 According to a Galectin Therapeutics media release, the company will issue a press release announcing the results of this trial on December 5, 2017. The company will host a conference call and webcast, including a slide presentation.
    • 07 Nov 2017 According to a Galectin Therapeutics media release, all patients in this trial have completed all 52 weeks of infusions and 100% of the doses have been administered.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top